argenx Karen Massey to become new CEO
argenx announced that Karen Massey, current COO, will transition to CEO and executive director and Tim Van Hauwermeiren, current CEO, will transition to non-executive director and chairman of the board. We believe Karen is a strong fit for the CEO role as an internal candidate who, in her capacity as COO, helped shape the company's Vision 2030 and built its commercial engine. Based on our conversation with management, Karen will focus on ensuring continuity and executing argenx' strategy, while navigating the company through its next stage of growth. BUY and €900 TP maintained.News: argenx announced that Karen Massey, current COO, will transition to CEO and executive director and Tim Van Hauwermeiren, current CEO, will transition to non-executive director and chairman of the board.
These changes are subject to shareholder approval at the Annual General Meeting on 6 May 2026, which allows for a comprehensive transition period.
Karen Massey joined argenx as Chief Operating Officer in March 2023, and has over 20 years of experience in the biopharma industry. Prior to joining argenx, Ms. Massey was with Genentech (Roche Group) for over nine years, where she most recently served as senior vice president of product development and global clinical operations. Ms. Massey holds a Bachelor of Economics from the University of Sydney and an MBA from the NYU Stern School of Business.
Peter Verhaeghe, who has been with argenx since its founding, will be retiring as current BOD chairman.
Our view: A big moment for argenx as Tim Van Hauwermeiren transitions to a new role as chairman of the board having led the company for 18 years as CEO, and will be succeeded by Karen Massey as new CEO. We believe Karen is a strong fit for the CEO role as an internal candidate who, in her capacity as COO, helped shape the company's Vision 2030 and built its commercial engine. As such, Karen plans to ensure continuity, executing argenx' strategy, while navigating the company through its next stage of growth. We note that Tim will remain involved in his new role as chairman of the board, and will act as a sounding board for management. BUY and €900 TP maintained.
Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.